

A novel role of Shc adaptor proteins in steroid hormone-regulated cancers

Syed Mahfuzul Alam^{1*}, Mythilypriya Rajendran^{1*}, Shouqiang Ouyang¹, Suresh Veeramani¹, Li Zhang¹ and Ming-Fong Lin^{1,2}

¹Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, 985870 Nebraska Medical Center, Omaha, Nebraska 68198-5870, USA

²Eppley Institute for Cancer Research, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA

(Correspondence should be addressed to M-F Lin; Email: mlin@unmc.edu)

*S M Alam and M Rajendran contributed equally to this work

Abstract

Tyrosine phosphorylation plays a critical role in growth regulation, and its aberrant regulation can be involved in carcinogenesis. The association of Shc (Src homolog and collagen homolog) adaptor protein family members in tyrosine phosphorylation signaling pathway is well recognized. Shc adaptor proteins transmit activated tyrosine phosphorylation signaling that suggest their plausible role in growth regulation including carcinogenesis and metastasis. In parallel, by sharing a similar mechanism of carcinogenesis, the steroids are involved in the early stage of carcinogenesis as well as the regulation of cancer progression and metastatic processes. Recent evidence indicates a cross-talk between tyrosine phosphorylation signaling and steroid hormone action in epithelial cells, including prostate and breast cancer cells. Therefore, the members of Shc proteins may function as mediators between tyrosine phosphorylation and steroid signaling in steroid-regulated cell proliferation and carcinogenesis. In this communication, we discuss the novel roles of Shc proteins, specifically p52^{Shc} and p66^{Shc}, in steroid hormone-regulated cancers and a novel molecular mechanism by which redox signaling induced by p66^{Shc} mediates steroid action via a non-genomic pathway. The p66^{Shc} protein may serve as an effective biomarker for predicting cancer prognosis as well as a useful target for treatment.

Endocrine-Related Cancer (2009) 16 1–16

Introduction

Cancers in steroid hormone-responsive tissues presently account for more than 35% in men and more than 40% in women of all newly diagnosed cancers in the United States (Henderson & Feigelson 2000). Extensive research has clearly demonstrated that the abnormal changes in the levels, frequencies, and types of steroid hormones are important contributors to the development of major cancer types such as the cancers of the prostate (androgen, estrogen), testes (*in utero* estrogen), breast (estrogen, progesterone), ovary (FSH, estrogen, androgen), uterine endometrium (estrogen), and thyroid (TSH, estrogen; Henderson & Feigelson 2000). Thus, many studies have been focused on the involvement of steroids in the regulation of tumor development, cancer cell

proliferation, progression, and metastatic processes. It is now evident that either in the early stage of carcinogenesis or in the advanced metastatic phenotype, steroid hormone action goes far beyond the classical receptor-mediated gene regulation. These steroid hormone-related cancers may share common mechanisms of carcinogenesis, such as DNA damage/mutation as well as the elevated levels of various growth factors induced by the excess of steroids, leading to aberrant growth regulation (Dickson & Lippman 1987, Dabrosin *et al.* 1997, Devanesan *et al.* 2001). Recent advances further indicate that these hormones could also induce rapid, non-genomic responses and a convoluted network of interactions with different intracellular signaling pathways.

Non-genomic actions by steroid hormones

Numerous studies have demonstrated the non-genomic action of steroid hormones, including androgens and estrogens, in cellular processes such as cell proliferation and motility (Berridge *et al.* 1998). The most intriguing facts on the non-genomic nature of steroids are that the effects depend on their rapid response and insisting no direct binding of nuclear receptors to gene expression, i.e., seconds to minutes and their insensitivity to the inhibitors of transcription and translation and/or the antagonists of the classical intracellular steroid hormone receptors. The non-genomic effects of steroids could be mediated by multiple pathways, and are discussed briefly as follows.

Direct and acute action of steroids

Steroids may have direct action on target molecules independent of steroid receptors. One such effect, for example, is the direct binding and activation of protein kinase C (PKC) isoforms such as PKC $_{\alpha}$ and PKC $_{\delta}$ by aldosterone and 17 β -estradiol (E $_2$) respectively via binding directly to their regulatory domains C $_2$ that mediates calcium (Ca $^{2+}$) binding and results in the autophosphorylation of these kinases (Alzamora & Harvey 2008). Furthermore, aldosterone and E $_2$ rapidly and directly stimulate phospholipase A2 (PLA $_2$) and cyclooxygenase (COX), which also result in the rapid increase in intracellular [Ca $^{2+}$] $_i$ (Harvey *et al.* 2002). The other direct and acute effects of steroids are their rapid action on voltage-gated and calcium-activated ion channels. E $_2$ activates the calcium-activated potassium channels via binding directly to its regulatory β -subunit (Valverde *et al.* 1999). Testosterone rapidly activates ATP-sensitive K $^+$ channels (K $_{ATP}$) via opening K $_{ATP}$ channels (Er *et al.* 2004) and inhibits the L-type and T-type calcium channels (I $_{Ca,L}$; Michels *et al.* 2006, Er *et al.* 2007).

Rapid action of steroids involving classical intracellular steroid receptors

Steroids may bind to the classical intracellular steroid receptors and activate the second messenger pathways such as c-Src kinase that rapidly stimulate the MAPK/ERK and PI3K/AKT kinase pathways (Migliaccio *et al.* 2000). Interestingly, an androgen receptor (AR)/Src/modulator of non-genomic action of estrogen receptor (MNAR) complex and the cooperative association of c-Src, estrogen receptors (ERs), and AR activates MAPK and c-Src kinase pathways respectively (Kousteni *et al.* 2001, Unni *et al.* 2004).

Estrogens on binding to ER α may also serve as a transcriptional co-activator activating several transcriptional factors, such as activator protein 1 (AP-1), nuclear factor kappa B (NF- κ B), and SP-1 in a non-genomic manner (Ray *et al.* 1997, Jakacka *et al.* 2001, Safe 2001). Steroids can also activate cAMP-dependent protein kinase A (PKA) via the transmembrane sex hormone-binding globulin (SHBG) receptor in association with transmembrane G-protein-coupled receptor (GPCR; Fortunati 1999, Rosner *et al.* 1999). The activation of PKA via the induction of cAMP by SHBG is observed in both prostate and breast cancer cells (Fortunati *et al.* 1996, Nakhla *et al.* 1997).

Rapid action of steroids involving non-classical membrane-bound steroid receptors

Steroids may undergo non-genomic action by binding to distinct non-classical membrane-bound steroid receptors. Several reports have presumed the presence of androgen- and estrogen-binding sites in a number of cells (Benten *et al.* 1999a,b, Armen & Gay 2000, Kampa *et al.* 2002). Interestingly, both the membrane androgen receptor (mAR) and the membrane ER (mER) are found to be associated with an integral membrane protein caveolin that facilitates the assembling of several signaling molecules, including phosphatidylinositol 3-kinase (PI3K), Ras, and Src kinase in their scaffold domain (Okamoto *et al.* 1998, Kim *et al.* 1999, Lu *et al.* 2001). Furthermore, mER perhaps exists as in a cytoplasmic pool and the rapid action requires their interaction with caveolin in association with MNAR, Shc and growth factor receptors, and striatin that translocated ER to the plasma membrane (Wong *et al.* 2002, Lu *et al.* 2004, Song *et al.* 2005).

Rapid action of membrane steroid receptors involving GPCR

The most preserved non-genomic action of steroid hormones is the rapid increase in intracellular calcium concentration [Ca $^{2+}$] mediated via GPCR that constitutes α -, β -, and γ -subunits (Lieberherr & Grosse 1994, Benten *et al.* 1998), which ultimately results in the rapid activation of MAPK/ERK and PI3K/AKT pathways, leading to the activation of PKC and PKA (Kelly *et al.* 1999, Estrada *et al.* 2003). The interaction of mAR with GPCR results in the dissociation of G α -subunit and the signal is transmitted from G $\beta\gamma$ through the activation of effector molecules including c-Src, Raf, and phospholipase C (PLC; Pierce *et al.* 2002). GPCR itself may also serve as the membrane receptor, i.e., binding of E $_2$ to an orphan GPCR, termed

GPR30, plays a critical role in the rapid signaling of E₂-mediated stimulation of Ras-dependent MAPK activation through the phosphorylation of Shc (Luttrell *et al.* 1996).

Rapid action of membrane steroid receptors via trans-activation of growth factor receptors

The rapid non-genomic actions of membrane steroid receptors may function via trans-activation of the growth factor receptors (Levin 2005), and of all membrane steroid receptors, mER is the paramount and well studied. The phenomenon is further confirmed by the co-existence of endogenous membrane receptors, including AR and ER, G-proteins, GPCR, growth factor receptors (EGFR, IGFR), non-receptor tyrosine kinases (Src, Ras), and linker proteins such as MNAR and striatin in the plasma membrane termed as 'signalosomes' (Hammes & Levin 2007). Alternatively, steroids may activate growth factor receptor kinase activity by inhibiting the regulatory phosphatases (Meng *et al.* 2000).

Rapid non-transcriptional action of membrane steroid receptors

The other non-genomic action of steroids involving membrane receptors is the non-transcriptional effects of these receptors that provoke the posttranslational amendments including phosphorylation. By regulating kinases and phosphatases, steroids influence the cell functions such as cell motility via modifying actin cytoskeleton (Kampa *et al.* 2002, Meyer & Feldman 2002, Levin 2005).

Rapid action of steroids on membrane fluidity

Steroids may mediate the non-genomic fashion through changes in membrane flexibility. Androgens via interacting with phospholipids in the lipid bilayer decrease the membrane fluidity, and subsequently alter the function of Na⁺/K⁺ and Ca²⁺ ATPase systems and also influence cellular adhesion and cell–cell interaction (Duval *et al.* 1983, Van Bömmel *et al.* 1987).

In summary, we propose that though the non-genomic actions of steroids are mediated through multiple pathways, both genomic and non-genomic effects are interlinked as non-genomic actions of steroids ultimately influencing at least one of the classical genomic-mediated transcriptional activities. Nevertheless, the molecular mechanisms of steroids, especially androgens and estrogens, in both the development and progression of human endocrine-related cancers at the non-genomic levels need further investigations. Along with these observations, in this

review, we emphasize a novel non-genomic action of steroids promoting various stages of carcinogenesis via Shc proteins.

Cross-talk of tyrosine phosphorylation signaling and steroids in carcinogenesis

Every step of carcinogenesis is essentially controlled by various growth factors and their receptors, either it is steroid regulated or not. Growth factors, including nerve growth factor (Engebraaten *et al.* 1993, Sachs *et al.* 1996), fibroblast growth factor (Mignatti *et al.* 1991, Engebraaten *et al.* 1993, Taylor *et al.* 1993), platelet-derived growth factor (Engebraaten *et al.* 1993, Choudhury *et al.* 1997), epidermal growth factor (EGF; Engebraaten *et al.* 1993, Hamada *et al.* 1995), keratin growth factor (Sachs *et al.* 1996), hepatocyte growth factor (Pelicci *et al.* 1995, Sachs *et al.* 1996), interleukin 2 (Ratner *et al.* 1992), insulin, and insulin-like growth factors (Stracke *et al.* 1989) are known to be involved in regulating cell proliferation, motility, invasion, and/or migration of various cell types. The activated receptors triggered by growth factors, cytokines, or adhesion molecules facilitate the docking of Src homology 2 (SH2) and phosphotyrosine-binding (PTB) domain-containing adaptor molecules that transduce signals via downstream intracellular cascades. Each of the receptors for the ligands described above activates the c-Src homology and collagen homolog (Shc) adaptor proteins for signal transduction, which suggests a conceivable role of the Shc proteins in various stages of carcinogenesis.

Recently, several lines of evidence indicate that Shc proteins mediate diverse biological activities; for example, they may mediate steroid actions other than serving as adaptors in tyrosine phosphorylation signaling. Since the role of Shc proteins in mediating tyrosine phosphorylation signaling and in regulating oxidative stress-induced apoptosis has received much attention (Migliaccio *et al.* 1997, 1999, Ravichandran 2001), in this communication, we will first briefly overview Shc proteins and then focus our efforts on discussing the novel roles of Shc proteins, specifically p52^{Shc} and p66^{Shc}, in steroid-regulated cancers.

Members of Shc family: structure and function in tyrosine phosphorylation signaling

Molecular structure of Shc isoforms

Shc proteins were first cloned using an SH2-coding sequence as a probe, and the Shc family includes three

isoforms with molecular masses of 46, 52 and 66 kDa, which are encoded by the same gene at chromosome 1q21 (Pelicci *et al.* 1992). A promoter in the first intron of Shc locus transcribes the mRNA of p66^{Shc}, whereas an alternate promoter and splicing generates the other two Shc isoforms, i.e., p46^{Shc} and p52^{Shc} (Ventura *et al.* 2002). These three isoforms of Shc protein contain overlapping amino acid sequences that contribute to a SH2 domain at the COOH-terminal and a PTB domain at the NH₂-terminal, separated by a central region enriched in proline and glycine residues, i.e., collagen homology (CH1) domain (Ravichandran 2001), as shown in Fig. 1. The SH2 domain (~100 amino acids) is the prototype for protein–protein interaction modules that mediate the formation of multiprotein complexes during signaling (Pawson & Scott 1997, Yoshida *et al.* 2004). Structurally, p66^{Shc} differs from p52^{Shc} and p46^{Shc} by virtue of its unique NH₂-terminal, a 110-amino acid CH₂ region, which is also rich in proline and glycine residues (Migliaccio *et al.* 1997).

Subcellular localization of Shc isoforms

p66^{Shc} is expressed primarily in epithelial cells, while p52^{Shc} and p46^{Shc} are expressed ubiquitously (Migliaccio *et al.* 1997). Most of p66^{Shc} protein is distributed throughout the cytosol and a fraction of p66^{Shc} localizes within the inner membrane and intermembrane spaces of mitochondria (Orsini *et al.* 2004, Ventura *et al.* 2004, Giorgio *et al.* 2005, Nemoto *et al.* 2006). p46^{Shc} is found to be localized in the mitochondrial matrix (Orsini *et al.* 2004, Ventura *et al.* 2004, Nemoto *et al.* 2006). Unlike p46^{Shc} and p66^{Shc}, p52^{Shc} is translocated to the plasma membrane from cytosol upon stimulation by growth factors, e.g., EGF (Migliaccio *et al.* 1997).




Figure 1 A schematic organization of Shc isoforms. The Shc proteins include three isoforms that are encoded by the same gene. They contain overlapping sequences. Three major tyrosine phosphorylation sites have been identified within the CH1 domain in all Shc isoforms. The unique CH2 domain of p66^{Shc} isoform consists of 110 amino acids and contains a serine phosphorylation site (Ser-36). The PTB domain of p46^{Shc} is deficient of the first 46 amino acids.

Shc isoforms in tyrosine phosphorylation signaling

p46^{Shc}

Shc proteins are expressed in distinct patterns and exhibit diverse biological functions. Ventura *et al.* (2004) have reported specifically p46^{Shc} as the first example to be localized in the mitochondrial matrix by means of a mitochondrion-targeting signal, which is inactive in p52^{Shc} and p66^{Shc}. Thus, p46^{Shc} may play a role in the signal transduction pathways regulating mitochondrial physiology (Ventura *et al.* 2004). In addition to mediating tyrosine phosphorylation signaling (McGlade *et al.* 1992, Migliaccio *et al.* 1997), p46^{Shc} may also modulate steroid action since steroids can regulate mitochondrial enzymatic activities (Ripple *et al.* 1997, 1999). Nevertheless, due to the limited studies on p46^{Shc} in steroid action in carcinogenesis, it will not be discussed further in this communication.

p52^{Shc}

p52^{Shc} is responsible for transducing anchorage-dependent growth signaling (Pelicci *et al.* 1992). In general, when cells are stimulated by growth factors, p52^{Shc} is recruited and binds to tyrosine kinase receptors through its PTB or SH2 domain, leading to its phosphorylation at tyrosine residues 239, 240, and 317 within the CH1 domain (Fig. 1; Rozakis-Adcock *et al.* 1992, van der Geer *et al.* 1996, Gotoh *et al.* 1996). Upon tyrosine phosphorylation, p52^{Shc} recruits Grb2/SOS through a binding event between the SH2 domain of Grb2 and Shc phosphotyrosine residues (Pelicci *et al.* 1992, Rozakis-Adcock *et al.* 1992), which ultimately results in the activation of Ras and the MAPK cascade for mitogenesis (Fig. 2; Bonfini *et al.* 1996). The PTB domain of p52^{Shc} binds to the phosphorylated tyrosine residues of receptor protein tyrosine kinases and functions similar to the SH2 domain. The CH1 and CH2 domains are putative SH3-binding regions (Lotti *et al.* 1996). Studies have also suggested that p52^{Shc} mediates steroid action on cell proliferation as well as cell survival via tyrosine phosphorylation signal pathway (Kousteni *et al.* 2001, Lee *et al.* 2004a). Its aberrant expression and activation may lead to the dysregulation of one of the multi-pathways in carcinogenesis by steroids, a topic of focus in this review.

p66^{Shc}

p66^{Shc} is also phosphorylated at its tyrosine residues as p52^{Shc} and p46^{Shc} upon growth factor stimulation, e.g., EGF treatment, and forms complexes with Grb2.




Figure 2 A schematic representation of Shc proteins activating the Ras and MAP kinase cascade. Upon stimulation by growth factors, RTK undergoes dimerization and tyrosine phosphorylation. Subsequently, Shc proteins are recruited and phosphorylated on tyrosine residue via forming a complex with RTK through the SH2 and/or PTB domain of Shc. The phosphorylated Shc proteins then associate with Grb2 adaptor protein through its tyrosine phosphorylation site to the SH2 domain of Grb2; the latter is constitutively complexed with SOS through its SH3 domains. These events result in the translocation of SOS to the plasma membrane and subsequently activate membrane-bound Ras in the exchange of GDP for GTP and trigger the activation of MAP kinase cascade, resulting in cell proliferation, differentiation, migration, invasion, and survival.

However, there are certain functional differences between p66^{Shc} and the other two Shc members. Unlike p52^{Shc}, p66^{Shc} is unable to transform NIH3T3 mouse fibroblasts in culture (Migliaccio *et al.* 1999) and it could not augment EGF-induced extracellular signal-regulated kinases/mitogen-activated protein kinases (ERK/MAPK) activation in cell cultures such as HeLa, CHO, and COS-1 cells. One possible explanation is that increased expression of p66^{Shc} has resulted in an elevated level of the basal activity of ERK/MAPK in the absence of stimulus, which thus minimizes the extent of further activation by growth factors (Migliaccio *et al.* 1997, Okada *et al.* 1997, Veeramani *et al.* 2005b). Recently, the task of p66^{Shc} in mediating stress-induced apoptosis has received much attention (Migliaccio *et al.* 1999, Orsini *et al.* 2004, Giorgio *et al.* 2005). Once p66^{Shc} is phosphorylated at Ser-36 in its CH2 domain in response to various stress factors, such as H₂O₂, UV radiation, and chemicals, e.g., Taxol, a fraction of cytosolic p66^{Shc} associates with heat-shock proteins to mediate apoptotic response (Fig. 3; Orsini *et al.* 2004) and serves as an apoptotic sensitizer to those signals (Migliaccio *et al.* 1999). p66^{Shc} also acts as a negative regulator of human and mouse T-cell survival and proliferation

(Pacini *et al.* 2004). In parallel, p66^{Shc} knockout mice exhibit a prolonged life span by 30% and those mouse embryo fibroblast (MEF) cells have increased resistance to oxidative and hypoxic stress (Migliaccio *et al.* 1999, Trinei *et al.* 2002, Zaccagnini *et al.* 2004). Thus, p66^{Shc} may function as a longevity gene in mammals. Interestingly, p66^{Shc} expression level in human dermal fibroblasts increases with aging, opposite to the knockout mouse model (Pandolfi *et al.* 2005). Collectively, these data indicate that p66^{Shc} could function as a sensor and transduce signals in response to cellular stress while more studies are required for its role in human longevity.

Several lines of evidence suggest that aberrant expression of p66^{Shc} could be involved in various stages of carcinogenesis (Jackson *et al.* 2000, Luzi *et al.* 2000, Ravichandran 2001, Davol *et al.* 2003, Lee *et al.* 2004b, De *et al.* 2005, Grossman *et al.* 2007). However, the role and the molecular mechanisms of p66^{Shc} in this mode of regulation remain to be elucidated. In this review, we focus on discussing a novel functional role of p66^{Shc} adaptor protein involved in steroid-related carcinogenesis, leading to its metastasis. This member of Shc protein family may serve as a new target for preventing tumor progression and metastasis.

Role of Shc proteins in steroid-regulated tumor progression and metastasis

Tumor progression and metastasis are the features of cancer. Cell proliferation, migration, and adhesion to the target tissues are the critical steps that allow tumor cells to obtain the metastatic phenotype. The process of metastasis requires the interaction of malignant cells with at least three distinct microenvironments, including the primary organ, the circulation or lymphatic channels, and the target organ where a metastatic lesion will develop (Radinsky & Fidler 1992, Mundy




Figure 3 p66^{Shc} acting as a stress sensor and increasing intracellular ROS level. Increased ROS induces the phosphorylation of serine 36 at p66^{Shc} protein that promotes the generation of more ROS, leading to cell proliferation, adhesion, migration, or apoptosis.

1997, Cooper *et al.* 2003). Within these microenvironments, several factors are involved in the metastatic cascade (Gopalkrishnan *et al.* 2001). Tumor cells, after reaching to target organs and tissues, establish as successful foci in the conducive environments. Subsequently, tumor cells proliferate in the new, supportive microenvironment as micrometastasis where they induce angiogenesis for maintaining the growth of new lesion. Induction of angiogenesis is necessary for successful metastasis to meet the nutrient requirements when the tumor size becomes more than 2 mm in size (Ellis & Fidler 1996, Gopalkrishnan *et al.* 2001). Cell proliferation and migration depend on intracellular signals transmitted by the growth factors and adhesion proteins within the extracellular matrix (Pages *et al.* 1993). Both these processes employ many common intracellular signaling molecules, e.g., Rho family proteins and ERK cascades (Pages *et al.* 1993, Olson *et al.* 1995, Anand-Apte *et al.* 1997, Klemke *et al.* 1997). It is evident now that Shc isoforms, specifically p52^{Shc} and p66^{Shc}, play a crucial role in cell migration and adhesion, in addition to their roles in mediating cell proliferation induced by growth factor receptor signaling (Fig. 4; Klemke *et al.* 1994, Huttenlocher *et al.* 1995). These processes involve the rearrangement of actin cytoskeleton, the formation of new integrin substratum contacts, cell contraction, and the release of pre-existing cell-matrix contacts (Lauffenburger & Horwitz 1996). We will thus discuss the role of p52^{Shc} and p66^{Shc} in these processes and emphasize on steroid regulation.

Role of p52^{Shc} in steroid-regulated cell proliferation and migration

In addition to the classical role in mediating tyrosine kinase-activated pathways, p52^{Shc} functions as a primary adaptor protein for mediating the mitogenic signals of steroids at the non-genomic level in human breast and prostate cancer cells (Stevenson *et al.* 1999, Lee *et al.* 2004a). In prostate cancer, the data clearly showed that p52^{Shc} is responsible for transducing androgen-activated ErbB-2 signaling, which leads to prostate cancer cell proliferation (Lee *et al.* 2004a). This androgen-stimulated cell proliferation requires Y317 phosphorylation since p52^{Shc} Y317F mutant effectively abolishes androgen stimulation, and that inhibition occurs at certain phases of the cell cycle (Lee *et al.* 2004a). This observation on the role of p52^{Shc} in androgen action on prostate cancer cells is in parallel to that of p52^{Shc} in estrogen action on breast cancer cells, correlating with ErbB-2 activity (Stevenson & Frackelton 1998). In addition, vitamin D treatment

caused a significant decrease in LNCaP cell growth, which is closely associated with the reduction in ErbB-2 activity and its downstream signaling mediator p52^{Shc} via dephosphorylating Y317, thereby emphasizing the involvement of tyrosine phosphorylation of p52^{Shc} in human prostate cancer cell proliferation (Stewart *et al.* 2005). Furthermore, the p52^{Shc} Y317F mutant blocks estrogen-induced cell cycle progression at both the G₀-G₁ and G₂-M junctions (Stevenson *et al.* 1999). Additionally, in the presence of steroids, ER α -transfected HeLa cells exhibit chemoresistance, where p52^{Shc} mediates the anti-apoptotic activity of steroids and thus prevents those cells from etoposide-induced apoptosis (Kousteni *et al.* 2001). Clearly, p52^{Shc} plays a critical role in mediating steroid action, at least in part, via tyrosine phosphorylation non-genomic signaling.

p52^{Shc} may also be involved in the adhesion process of cancer cells. In rapidly adhering prostate cancer cells, e.g., LNCaP C-81 and PC-3 cells, the phosphorylation level of p52^{Shc} protein at Y317 correlates with ErbB-2 activation, higher than in slow-adhering LNCaP C-33 cells (Lee *et al.* 2004a, Yuan *et al.* 2007). Yet, both the adhesion rate and the Y317 phosphorylation of p52^{Shc} as well as ErbB-2 tyrosine phosphorylation level in slow-adhering LNCaP C-33 cells can be up-regulated by steroids. Thus, by correlating tyrosine phosphorylation and adhesion, p52^{Shc} may play a crucial role in the adhesion of cancer cells during steroid hormone-induced metastasis. Furthermore, a direct involvement of p52^{Shc} in breast cancer metastasis in transgenic mice that express polyomavirus middle T antigen with a mutated Shc-binding site has been demonstrated (Webster *et al.* 1998). Polyomavirus middle T antigen couples with and activates signaling molecules, such as Src, Shc, and phosphatidylinositol 3'-kinase (PI3K) for its oncogenic capacity. Importantly, in transgenic mice, which have metastatic tumors, the mutated p52^{Shc}-binding site on middle T antigen had reverted to the wild type and regained its function, thus emphasizing the potential importance of the functional p52^{Shc} in the process of metastasis *in vivo* (Webster *et al.* 1998). In addition, it has been revealed that in integrin signaling, Shc recruitment to the actin-associated cytoskeleton is important (McGlade *et al.* 1992, Schlaepfer *et al.* 1998, Wary *et al.* 1998). p52^{Shc} potentiates integrin signaling, and integrin ligation results in the activation of non-receptor tyrosine kinases, such as Src, Fyn, and focal adhesion kinase (FAK), which phosphorylates p52^{Shc}, leading to Ras activation and entering into the cell cycle (McGlade *et al.* 1992, Mainiero *et al.* 1995, Wary *et al.* 1996, 1998). Besides, the SH3 domain of




Figure 4 Involvement of p66^{Shc} and p52^{Shc} in tumor metastasis. Growing primary tumors attract new blood vessels, i.e., angiogenesis, and lymphatic vessels, i.e., lymphangiogenesis, to promote local tumor growth, involvement of regional lymph nodes, and finally distant metastasis. In the process of metastasis after degrading or remodeling the basement membrane, metastatic cells detach from the primary tumor mass, intravasate, survive the stress of vascular transportation, and then evade host defense mechanism, which are in part regulated by the adaptor proteins p52^{Shc} and p66^{Shc}. Furthermore, targeting via microvessels and cell adhesion molecules, the increased phosphorylation of p52^{Shc} and p66^{Shc} proteins mediate the proliferation of tumor cells that metastasize to their preferred sites after extravasation into the target organ parenchyma, and are permitted to reside in the target tissue in which cancer cells respond to transendothelial growth factors from that specific organ. (The figure is adapted from La Porta 2000).

Fyn interacts with the proline-rich region in the CH1 domain of p52^{Shc} (Thomas & Bradshaw 1997) and the amino-terminal domain of p52^{Shc} is shown to mediate the association of this adaptor protein to an actin-rich cellular fraction (Thomas & Bradshaw 1997). Additionally, a mutation of the PTB domain (S154P-p52^{Shc}) abolishes integrin-induced p52^{Shc} tyrosine phosphorylation where the SH2 domain of p52^{Shc} is dispensable (Collins *et al.* 1999). p52^{Shc} phosphorylation by c-Src can be augmented when the PTB domain binds to phospholipids (Zhou *et al.* 1995, Sato *et al.* 1997). These observations explain how the PTB domain localizes p52^{Shc} to the membrane where it becomes phosphorylated by cytoskeleton-associated tyrosine kinases, which finally results in cell migration. It should be noted that these non-receptor tyrosine kinases, e.g., Src, closely interact with steroid hormone

signaling pathway (Migliaccio *et al.* 2000, Guo *et al.* 2006). The molecular mechanism by which steroids induce cell adhesion and/or migration via p52^{Shc} requires further investigation.

Role of p66^{Shc} in steroid-regulated cell proliferation

In tyrosine phosphorylation signal transduction pathway, p66^{Shc} conventionally known as an adaptor protein. Interestingly, p66^{Shc} expression closely correlates with the growth rate of prostate cancer cells. For example, p66^{Shc} protein levels in the rapidly growing cells, e.g., PC-3 and DU145, are approximately 4- to 13-fold higher than that in the slow-growing LNCaP C-33 cells and are over tenfold higher than that in even slower MDA PCa2b cells (Veeramani *et al.* 2005b). Recent data indicate that

p66^{Shc} may play a critical role in mediating steroid-stimulated cell proliferation. In the presence of steroid hormones (androgen and estrogen), p66^{Shc} protein level as well as cell proliferation rate is increased in hormone-sensitive human prostate (LNCaP C-33 and MDA PCa2b), testicular (Tera-1 and Tera-2), and breast (MCF-7) cancer cells, higher than those cells cultured in the absence of steroids (Lee et al. 2004b). Thus, steroids increase p66^{Shc} protein level and concurrently cell growth.

To elucidate directly the functional role of p66^{Shc} protein in steroid-regulated cells, both cDNA and siRNA approaches were employed (Veeramani et al. 2005b). In both p66^{Shc} cDNA, transiently transfected cell population and stable subclones of slow-growing LNCaP C-33 cells, elevated expression of p66^{Shc} correlates with increased cell proliferation. On the contrary, a decreased cell growth rate is observed when p66^{Shc} protein is knocked down by its siRNA in the rapidly growing LNCaP C-81 and PC-3 cells. The data clearly establish the causal relationship of p66^{Shc} protein and cell growth. Furthermore, p66^{Shc} mediates growth stimulation by androgens (Veeramani et al. 2008). The clinical relevance of these data is supported by the observations that in prostate cancer archival specimens, p66^{Shc} protein level is significantly higher in prostate adenocarcinomatous cells than in adjacent benign glandular cells (Lee et al. 2004b). Similarly, the expression level of p66^{Shc} is elevated in metastatic breast, ovarian, and thyroid tumors and may serve as a useful prognostic marker for stage-IIA colon cancer (Jackson et al. 2000, Abdollahi et al. 2003, Park et al. 2005, Grossman et al. 2007). Nevertheless, some studies showed that p66^{Shc} protein is down-regulated in the primary tumors of breast cancers (Daval et al. 2003). Due to the potential importance of p66^{Shc} in carcinogenesis, further studies are needed to clarify the correlation of p66^{Shc} expression with breast cancer. In summary, cross-talks between tyrosine phosphorylation signaling and steroid hormones have been well established (Weigel 1996, Meng et al. 2000, Grossmann et al. 2001, Guo et al. 2006, Kraus et al. 2006, Migliaccio et al. 2006, Weigel & Moore 2007); it is thus reasonable to propose that p66^{Shc} mediates steroid action in steroid-responsive epithelial cells. We therefore hypothesize that the elevated level of p66^{Shc} protein in steroid-related cancer cells plays a critical role in up-regulating those cancer cell proliferation and thus contributes to the tumorigenicity of those cancers (Fig. 2). The role of p66^{Shc} in this mode of regulation requires further investigation.

Role of p66^{Shc} in metastasis

Several studies have shown the involvement of p66^{Shc} in cellular invasion, motility, migration, and/or metastasis. Jackson et al. (2000) have shown that xenograft bone metastasis of breast cancer cell line, MDA-MB-231, expresses p66^{Shc} and its metastatic variant F-11 cells have a threefold higher p66^{Shc} expression level. Furthermore, increased expression of p66^{Shc} in lymph node-positive breast cancers correlates with an increased number of positive lymph nodes (Jackson et al. 2000). As higher levels of p66^{Shc} protein are observed in breast cancer specimens with higher metastatic potential, it suggests the possibility that p66^{Shc} influences cell motility and invasion other than the MAPK pathway (Jackson et al. 2000). Furthermore, Northey et al. (2008) have demonstrated that decrease in the ShcA levels or the expression of a dominant-negative ShcA mutant blocked TGF- β -induced motility and the invasion of Neu/ErbB-2-expressing breast cancer cells, thus exploiting the crucial role of p66^{Shc} in the migration and invasion of cancer cells. In addition, elevated expression of p66^{Shc} by cDNA transfection in LNCaP C-33 cells is associated with increased motility and invasion (Yuan TC, Lin FF & Lin MF, unpublished data). In parallel, LNCaP C-81 and PC-3 prostate cancer cells express higher levels of p66^{Shc} and exhibit higher metastatic potential than LNCaP C-33 cells in xenograft animals (Veeramani et al. 2005b, Sebege J & Lin MF, unpublished observation). The observations on the increased expression of p66^{Shc}, but not p52^{Shc} or p46^{Shc}, in cell lines with higher metastatic ability and in the node-positive primary breast cancers also imply that p66^{Shc} functions in metastatic pathway.

Integrins play a vital role in cancer progression because of their ability to regulate various intracellular signaling molecules that are essential for cell motility, cell survival, and proliferation (Ruoslahti & Reed 1994, Hynes et al. 1999). It has been suggested that $\alpha_v\beta_3$ integrin plays a critical role in the metastasis of cancer cells to bone marrow (Cooper et al. 2002). $\alpha_v\beta_3$ integrin is expressed in breast and lung cancer cells that were originally derived from the bone marrow aspirates. $\alpha_v\beta_3$ is also expressed in highly tumorigenic, bone foci-derived human PC-3 prostate cancer cells, but not in low tumorigenic, lymph node foci-derived LNCaP cells (Zheng et al. 1999). The results of recent studies suggest that activated $\alpha_v\beta_3$ integrin regulates tumor growth *in vivo* by influencing VEGF expression. The up-regulation of VEGF expression depends on $\alpha_v\beta_3$ clustering where it promotes the recruitment of p66^{Shc} and subsequently the phosphorylation of

β_3 -associated p66^{Shc}. Phosphorylation of p66^{Shc} is a critical step for $\alpha_v\beta_3$ -mediated potentiation of VEGF expression and tumor vascularization *in vivo* (De *et al.* 2005). These findings provide insights into the role of $\alpha_v\beta_3$ and p66^{Shc} interaction as a regulator of tumor metastasis and angiogenesis. Thus, down-regulation of p66^{Shc} inhibits VEGF expression as well as the tumor growth and angiogenesis *in vivo* (De *et al.* 2005). Although the molecular mechanism of p66^{Shc} involvement in metastasis requires further investigations, it is hypothesized that p66^{Shc} is involved in an early step of invasion or during cell motility (Jackson *et al.* 2000) and plays a role in steroid-regulated metastatic process.

Molecular mechanisms of p66^{Shc}-mediated steroid action

In determining the prostate origin of metastatic cancers, cellular prostatic acid phosphatase (cPACp) has been used as a biomarker, due to its cell-specific expression (Sakai *et al.* 1992, Chu & Lin 1998). The results of several studies collectively indicate that cPACp exhibit the growth inhibitory activity by functioning as a PTPase (Lin & Meng 1996, Lin *et al.* 2001, Veeramani *et al.* 2005a). In parallel, the expression level of cPACp negatively correlates with prostatic carcinogenesis, i.e., the level of cPACp decreases in prostate cancer cells, lower than that in the adjacent non-cancerous cells (Reif *et al.* 1973, Foti *et al.* 1977, Loor *et al.* 1981, Chu & Lin 1998, Lin *et al.* 2001). Interestingly, in prostate cancer cells, the level of p66^{Shc} protein shows an inverse correlation with cPACp expression and has a positive correlation with Erb2 as well as ERK/MAPK activation (Veeramani *et al.* 2005b). In cPACp cDNA-transfected stable subclone cells, p66^{Shc} protein level is decreased and ErbB-2 as well as ERK/MAPK activity is diminished, correlating with decreased cell proliferation (Veeramani *et al.* 2005b). Conversely, elevated p66^{Shc} protein level as well as ErbB-2 and ERK/MAPK activation is observed in cPACp-inhibited LNCaP C-33 cells by inhibitors (Veeramani *et al.* 2005b). Similarly, in breast cancer cells, elevated expression of p66^{Shc} protein correlates with ErbB-2 and/or MAPK1/MAPK activation (Stevenson & Frackelton 1998, Lee *et al.* 2004b). In addition, the up-regulation of p66^{Shc} is shown in human ovarian, oral, and lung cancer cells expressing increased levels of ErbB-2 (Xie & Hung 1996). While the molecular mechanism of this inverse relationship between cPACp and p66^{Shc} protein remains to be investigated further, it should be noted that the inverse correlation of cPACp with p66^{Shc} as well as ERK/MAPK activation is

clinically relevant (Loor *et al.* 1981, Pontes *et al.* 1981, Solin *et al.* 1990, Sakai *et al.* 1993, Gioeli *et al.* 1999, Price *et al.* 1999, Lin *et al.* 2001, Lee *et al.* 2004b). Despite the fact that cPACp may serve as a good prognostic marker for metastatic prostate cancers (Sakai *et al.* 1993), because of decreased cPACp level upon tumor progression as well as increased p66^{Shc} protein level in PCa cells, we contemplate that the p66^{Shc}/cPACp ratio may serve as a competitive surrogate biomarker for predicting the prognosis of advanced prostate carcinoma.

Furthermore, p66^{Shc} may mediate steroid-stimulated cell proliferation via a non-genomic signaling pathway. In the rapidly growing cells, including steroid-stimulated cells, increased oxidative stress by the generation of reactive oxygen species (ROS) might contribute to the elevated p66^{Shc} protein level. p66^{Shc} protein can function as a stress sensor and is involved in regulating the intracellular level of ROS (Trinei *et al.* 2002). Activated metabolic reactions in the rapidly growing cells lead to increased production of ROS (Klaunig & Kamendulis 2004), which may in turn increase p66^{Shc} protein levels to mediate oxidative stress signals (Fig. 3). Evidently, upon H₂O₂ treatment, in MEF cells or DLD-1 colorectal cancer cells, the expression level of p66^{Shc} protein is increased (Trinei *et al.* 2002, Pacini *et al.* 2004). Additionally, ROS-induced phosphorylation of p66^{Shc} protein at Ser-36 residue further promotes the generation of ROS (Nemoto & Finkel 2002, Orsini *et al.* 2004). Notably, recent studies reveal that p66^{Shc} protein exhibits endogenous oxidase activity and its amino terminus contains a redox center, which is involved in electron transfer from cytochrome *c* to molecular oxygen and produces H₂O₂. This H₂O₂ mediates the opening of transition pores resulting in increased mitochondrial permeability and thus an abnormal high level of H₂O₂ can lead to apoptosis (Giorgio *et al.* 2005). Nevertheless, physiological levels of H₂O₂ function as growth stimuli. In addition to the above findings, p66^{Shc} may also increase H₂O₂ production through Rac1-SOS-specific pathway (Khanday *et al.* 2006), possibly leading to androgen-independent cell proliferation (Knight-Krajewski *et al.* 2004). ROS therefore mediates diverse biological functions, including cell proliferation, cell adhesion, migration, and apoptosis (Fig. 3).

In prostate cancer archival specimens, the ROS level is higher in cancerous cells than in non-cancerous cells, correlating with the proliferation index (Lim *et al.* 2005). The functional role of ROS as a positive regulator of cell growth, including prostate cancer cells, is apparent in part by inhibiting the PTPase




Figure 5 A proposed scheme of steroid-regulated cancer progression via Shc proteins. Upon steroid activation, p52^{Shc} undergoes phosphorylation at Y317 and promotes tumor growth at least in part via transducing signals through the Grb2–Ras–MAPK pathway. Like p52^{Shc}, p66^{Shc} protein also promotes tumor progression, nevertheless, via mediating oxidative stress signals through the generation of ROS. Upon stimulation by steroids, p66^{Shc} is translocated to mitochondria via Ser-36 phosphorylation-independent manner resulting in the generation of ROS. ROS may then inhibit PTP, resulting in RPTK activation, ERK/MAPK activation, and promote cell proliferation, survival, and migration, which collectively lead to metastasis.

activity, and thus the corresponding RPTK can be activated (Finkel & Holbrook 2000, Liu *et al.* 2002, Lou *et al.* 2008, Veeramani *et al.* 2008). Furthermore, steroid hormones, e.g., androgens and estrogens, and growth factors, such as EGF, can up-regulate ROS production in cells, as such; cell proliferation is promoted (Sundaresan *et al.* 1996, Liu *et al.* 2002). This is consistent with our findings that androgenic treatment of LNCaP C-33 cells promotes cell proliferation via decreasing cellular PACp and increasing p66^{Shc} protein level and ROS production as well as ErbB-2 tyrosine phosphorylation (Meng *et al.* 2000, Veeramani *et al.* 2008). Therefore, an inverse correlation of p66^{Shc} and cPACp in prostate cancer cell is observed. Additionally, it has been demonstrated that ROS may play a critical role in the initiation and/or early progression of prostate cancer; as such, anti-oxidants are used in clinical trials for this cancer prevention (Veeramani & Lin 2007). Collectively, the data indicate that p66^{Shc} can mediate non-genomic steroid action on cell proliferation and carcinogenesis including metastasis, while the molecular mechanisms require further investigations.

Conclusion and perspective

To discover the novel therapeutic targets for the prevention of tumor progression and metastasis, identifying the functional molecules that are involved in enhancing or suppressing these processes is one of the major challenges. The metastatic process in carcinogenesis is regulated dynamically by numerous factors, including growth factors, hormones, and extracellular matrices. To establish a metastatic lesion, tumor cells must complete all the steps in metastatic processes. Several studies have already shown that Shc proteins, including p52^{Shc} and p66^{Shc}, have marked effects on cell proliferation, invasion, and migration. In this review, we discuss a novel role of p52^{Shc} and p66^{Shc} in mediating steroid action on tumor proliferation and metastasis. We further present a novel non-genomic mechanism by which steroid signaling via p52^{Shc} and p66^{Shc} induces cancer cell proliferation, survival, migration and ultimately metastasis (Fig. 5). Nevertheless, the role of other key players engaged with p52^{Shc} and/or p66^{Shc} signaling pathway has yet to be identified. Thus, the molecular mechanisms by which p52^{Shc} and p66^{Shc} mediate steroid hormone-induced carcinogenesis require further investigations. Understanding the role of Shc adaptor proteins in cancer biology including the determination of the upstream regulators and downstream effectors of Shc functional pathways may lead to the development of novel anti-tumor strategies for targeting against steroid-induced epithelial cancers.

Declaration of interest

All authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This study was supported in part by the National Cancer Institute, National Institutes of Health (R01 CA88184), Department of Defense (W81XWH-06-1-0070 and W81XWH-08-1-0459), Nebraska Research Initiative for Cancer Glycobiology, and Nebraska Cancer and Smoking Disease Research Program LB 506 (2008-20).

Acknowledgements

We thank Ms Fen-Fen Lin for her tremendous help in our studies on Shc proteins.

References

- Abdollahi A, Gruver BN, Patriotis C & Hamilton TC 2003 Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells. *Biochemical and Biophysical Research Communications* **18** 188–197.
- Alzamora R & Harvey BJ 2008 Direct binding and activation of protein kinase C isoforms by steroid hormones. *Steroids* **73** 885–888.
- Anand-Apte B, Zetter BR, Viswanathan A, Qiu RG, Chen J, Ruggieri R & Symons M 1997 Platelet-derived growth factor and fibronectin-stimulated migration are differentially regulated by the Rac and extracellular signal-regulated kinase pathways. *Journal of Biological Chemistry* **272** 30688–30692.
- Armen TA & Gay CV 2000 Simultaneous detection and functional response of testosterone and estradiol receptors in osteoblast plasma membranes. *Journal of Cellular Biochemistry* **79** 620–627.
- Benten WP, Lieberherr M, Giese G & Wunderlich F 1998 Estradiol binding to cell surface raises cytosolic free calcium in T cells. *FEBS Letters* **422** 349–353.
- Benten WP, Lieberherr M, Giese G, Wrehlke C, Stamm O, Sekeris CE, Mossmann H & Wunderlich F 1999a Functional testosterone receptors in plasma membranes of T cells. *FEBS Journal* **13** 123–133.
- Benten WP, Lieberherr M, Stamm O, Wrehlke C, Guo Z & Wunderlich F 1999b Testosterone signaling through internalizable surface receptors in androgen receptor-free macrophages. *Molecular Biology of the Cell* **10** 3113–3123.
- Berridge MJ, Bootman MD & Lipp P 1998 Calcium – a life and death signal. *Nature* **395** 645–648.
- Van Bömmel T, Marsen T & Bojar H 1987 Effects of high-dose medroxyprogesterone acetate and various other steroid hormones on plasma membrane lipid mobility in CAMA-1 mammary cancer cells. *Anticancer Research* **7** 1217–1223.
- Bonfini L, Migliaccio E, Pelicci G, Lanfrancone L & Pelicci PG 1996 Not all Shc's roads lead to Ras. *Trends in Biochemical Sciences* **21** 257–261.
- Choudhury GG, Karamitsos C, Hernandez J, Gentilini A, Bardgette J & Abboud HE 1997 PI-3-kinase and MAPK regulate mesangial cell proliferation and migration in response to PDGF. *American Journal of Physiology* **273** F931–F938.
- Chu TM & Lin MF 1998 PSA and acid phosphatase in the diagnosis of prostate cancer. *Journal of Clinical Ligand Assay* **21** 24–34.
- Collins LR, Ricketts WA, Yeh L & Cheresch D 1999 Bifurcation of cell migratory and proliferative signaling by the adaptor protein Shc. *Journal of Cell Biology* **147** 1561–1568.
- Cooper CR, Chay CH & Pienta KJ 2002 The role of alpha(v)beta(3) in prostate cancer progression. *Neoplasia* **4** 191–194.
- Cooper CR, Chay CH, Gendernalik JD, Lee H-L, Bhatia J, Taichman RS, McCauley LK, Keller ET & Pienta KJ 2003 Stromal factors involved in prostate carcinoma metastasis to bone. *Cancer* **97** 739–747.
- Dabrosin C, Ollinger K, Ungerstedt U & Hammar M 1997 Variability of glutathione levels in normal breast tissue and subcutaneous fat during the menstrual cycle: an *in vivo* study with microdialysis technique. *Journal of Clinical Endocrinology and Metabolism* **82** 1382–1384.
- Davol PA, Bagdasaryan R, Elfenbein GJ, Maizel AL & Frackelton AR Jr 2003 Shc proteins are strong, independent prognostic markers for both node negative and node positive primary breast cancer. *Cancer Research* **63** 6772–6783.
- De S, Razorenova O, McCabe NP, O'Toole T, Qin J & Byzova TV 2005 VEGF-integrin interplay controls tumor growth and vascularization. *PNAS* **102** 7589–7594.
- Devanesan P, Santen RJ, Bocchinfuso WP, Korach KS, Rogan EG & Cavalieri E 2001 Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor-alpha knockout (ERKO)/Wnt-1 mice: implications for initiation of mammary tumors. *Carcinogenesis* **22** 1573–1576.
- Dickson RB & Lippman ME 1987 Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. *Endocrine Reviews* **8** 29–43.
- Duval D, Durant S & Homo-Delarche F 1983 Non-genomic effects of steroids. Interactions of steroid molecules with membrane structures and functions. *Biochimica et Biophysica Acta* **737** 409–442.
- Ellis LM & Fidler IJ 1996 Angiogenesis and metastasis. *European Journal of Cancer* **32A** 2451–2460.
- Engebraaten O, Bjerkgvig R, Pedersen PH & Laerum OD 1993 Effects of EGF, bFGF, NGF, and PDGF (bb) on cell proliferative, migratory, and invasive capacities of human brain-tumour biopsies *in vitro*. *International Journal of Cancer* **53** 209–214.
- Er F, Michels G, Gassanov N, Rivero F & Hoppe UC 2004 Testosterone induces cytoprotection by activating ATP-sensitive K⁺ channels in the cardiac mitochondrial inner membrane. *Circulation* **110** 3100–3107.
- Er F, Michels G, Brandt MC, Khan I, Haase H, Eicks M, Lindner M & Hoppe UC 2007 Impact of testosterone on cardiac L-type calcium channels and Ca²⁺ sparks: acute actions antagonize chronic effects. *Cell Calcium* **41** 467–477.
- Estrada M, Espinosa A, Muller M & Jaimovich E 2003 Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells. *Endocrinology* **144** 3586–3597.
- Finkel T & Holbrook NJ 2000 Oxidants, oxidative stress and the biology of ageing. *Nature* **9** 239–247.
- Fortunati N 1999 Sex hormone-binding globulin: not only a transport protein. What news is around the corner? *Journal of Endocrinological Investigation* **22** 223–234.

- Fortunati N, Fissore F, Fazzari A, Becchis M, Comba A, Catalano MG, Berta L & Frairia R 1996 Sex steroid binding protein exerts a negative control on estradiol action in MCF-7 cells (human breast cancer) through cyclic adenosine 30,50-monophosphate and protein kinase A. *Endocrinology* **137** 686–692.
- Foti AG, Cooper JF, Herschman H & Malvaez RR 1977 Detection of prostatic cancer by solid-phase radio-immunoassay of serum prostatic acid phosphatase. *New England Journal of Medicine* **297** 1357–1361.
- van der Geer P, Wiley S, Gish GD & Pawson T 1996 The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions. *Current Biology* **6** 1435–1444.
- Gioelli D, Mandell JW, Petroni GR, Frierson HF Jr & Weber MJ 1999 Activation of mitogen-activated protein kinase associated with prostate cancer progression. *Cancer Research* **59** 279–284.
- Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S, Marcaccio M et al. 2005 Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. *Cell* **122** 221–233.
- Gopalkrishnan RV, Kang DC & Fisher PB 2001 Molecular markers and determinants of prostate cancer metastasis. *Journal of Cellular Physiology* **189** 245–256.
- Gotoh N, Tojo A & Shibuya M 1996 A novel pathway from phosphorylation of tyrosine residues 239/240 of Shc, contributing to suppress apoptosis by IL-3. *EMBO Journal* **15** 6197–6204.
- Grossman SR, Lyle S, Resnick MB, Sabo E, Lis RT, Rosinha E, Liu Q, Hsieh CC, Bhat G, Frackelton AR Jr et al. 2007 p66 Shc tumor levels show a strong prognostic correlation with disease outcome in stage IIA colon cancer. *Clinical Cancer Research* **13** 5798–5804.
- Grossmann ME, Huang H & Tindall DJ 2001 Androgen receptor signaling in androgen-refractory prostate cancer. *Journal of the National Cancer Institute* **93** 1687–1697.
- Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD et al. 2006 Regulation of androgen receptor activity by tyrosine Phosphorylation. *Cancer Cell* **10** 309–319.
- Hamada J, Nagayasu H, Takayama M, Kawano T, Hosokawa M & Takeichi N 1995 Enhanced effect of epidermal growth factor on pulmonary metastasis and *in vitro* invasion of rat mammary carcinoma cells. *Cancer Letters* **89** 161–167.
- Hammes SR & Levin ER 2007 Extranuclear steroid receptors: nature and actions. *Endocrine Reviews* **28** 726–741.
- Harvey BJ, Doolan CM, Condliffe SB, Renard C, Alzamora R & Urbach V 2002 Non-genomic convergent and divergent signalling of rapid responses to aldosterone and estradiol in mammalian colon. *Steroids* **67** 483–491.
- Henderson BE & Feigelson HS 2000 Hormonal carcinogenesis. *Carcinogenesis* **21** 427–433.
- Huttenlocher A, Sandborg RR & Horwitz AF 1995 Adhesion in cell migration. *Current Opinion in Cell Biology* **7** 697–706.
- Hynes RO, Bader BL & Hodivala-Dilke K 1999 Integrins in vascular development. *Brazilian Journal of Medical and Biological Research* **32** 501–510.
- Jackson JG, Yoneda T, Clark GM & Yee D 2000 Elevated levels of p66 shc are found in breast cancer cell lines and primary tumors with high metastatic potential. *Clinical Cancer Research* **6** 1135–1139.
- Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD & Jameson JL 2001 Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. *Journal of Biological Chemistry* **276** 13615–13621.
- Kampa M, Papakonstanti EA, Hatzoglou A, Stathopoulos EN, Stournaras C & Castanas E 2002 The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cytoskeleton. *FEBS Journal* **16** 1429–1431.
- Kelly MJ, Lagrange AH, Wagner EJ & Rønnekleiv OK 1999 Rapid effects of estrogen to modulate G protein-coupled receptors via activation of protein kinase A and protein kinase C pathways. *Steroids* **64** 64–75.
- Khanday FA, Santhanam L, Kasuno K, Yamamori T, Naqvi A, Dericco J, Bugayenko A, Mattagajasingh I, Disanza A, Scita G et al. 2006 Sos-mediated activation of rac1 by p66shc. *Journal of Cell Biology* **172** 817–822.
- Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK & Jo I 1999 Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. *Biochemical and Biophysical Research Communications* **263** 257–262.
- Klaunig JE & Kamendulis LM 2004 The role of oxidative stress in carcinogenesis. *Annual Review of Pharmacology and Toxicology* **44** 239–267.
- Klemke RL, Yebra M, Bayna EM & Cheresch DA 1994 Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. *Journal of Cell Biology* **127** 859–866.
- Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P & Cheresch DA 1997 Regulation of cell motility by mitogen-activated protein kinase. *Journal of Cell Biology* **137** 481–492.
- Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES & Burnstein KL 2004 Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. *Oncogene* **23** 5513–5522.
- Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS et al. 2001 Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. *Cell* **104** 719–730.

- Kraus S, Gioeli D, Vomastek T, Gordon V & Weber MJ 2006 Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. *Cancer Research* **66** 11047–11054.
- Lauffenburger DA & Horwitz AF 1996 Cell migration: a physically integrated molecular process. *Cell* **84** 359–369.
- Lee MS, Igawa T & Lin MF 2004a Tyrosine-317 of p52(Shc) mediates androgen-stimulated proliferation signals in human prostate cancer cells. *Oncogene* **23** 3048–3058.
- Lee MS, Igawa T, Chen SJ, Van Bommel D, Lin JS, Lin FF, Johansson SL, Christman JK & Lin MF 2004b p66Shc protein is upregulated by steroid hormones in hormone-sensitive cancer cells and in primary prostate carcinomas. *International Journal of Cancer* **108** 672–678.
- Levin ER 2005 Integration of the extranuclear and nuclear actions of estrogen. *Molecular Endocrinology* **19** 1951–1959.
- Lieberherr M & Grosse B 1994 Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. *Journal of Biological Chemistry* **269** 7217–7223.
- Lim SD, Sun C, Lambeth JD, Marshall F, Amin M, Chung L, Petros JA & Arnold RS 2005 Increased Nox1 and hydrogen peroxide in prostate cancer. *Prostate* **62** 200–207.
- Lin MF & Meng TC 1996 Tyrosine phosphorylation of a 185 kDa phosphoprotein (pp185) inversely correlates with the cellular activity of human prostatic acid phosphatase. *Biochemical and Biophysical Research Communications* **226** 206–213.
- Lin MF, Lee MS, Zhou XW, Andressen JC, Meng TC, Johansson SL, West WW, Taylor RJ, Anderson JR & Lin FF 2001 Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. *Journal of Urology* **166** 1943–1950.
- Liu SL, Lin X, Shi DY, Cheng J, Wu CQ & Zhang YD 2002 Reactive oxygen species stimulated human hepatoma cell proliferation via cross-talk between PI3-K/PKB and JNK signaling pathways. *Archives of Biochemistry and Biophysics* **406** 173–182.
- Loor R, Wang MC, Valenzuela L & Chu TM 1981 Expression of prostatic acid phosphatase in human prostate cancer. *Cancer Letters* **14** 63–69.
- Lotti LV, Lanfrancione L, Migliaccio E, Zompetta C, Pelicci G, Salcini AE, Falini B, Pelicci PG & Torrisi MR 1996 Shc proteins are localized on endoplasmic reticulum membranes and are redistributed after tyrosine kinase receptor activation. *Molecular and Cellular Biology* **16** 1946–1954.
- Lou YW, Chen YY, Hsu SF, Chen RK, Lee CL, Khoo KH, Tonks NK & Meng TC 2008 Redox regulation of the protein tyrosine phosphatase PTP1B in cancer cells. *FEBS Journal* **275** 69–88.
- Lu ML, Schneider MC, Zheng Y, Zhang X & Richie JP 2001 Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. *Journal of Biological Chemistry* **276** 13442–13451.
- Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME & Karas RH 2004 Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. *PNAS* **101** 17126–17131.
- Luttrell LM, Hawes BE, van Biesen T, Luttrell DK, Lansing TJ & Lefkowitz RJ 1996 Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. *Journal of Biological Chemistry* **271** 19443–19450.
- Luzi L, Confalonieri S, Di Fiore PP & Pelicci PG 2000 Evolution of Shc functions from nematode to human. *Current Opinion in Genetics & Development* **10** 668–674.
- Mainiero F, Pepe A, Wary KK, Spinardi L, Mohammadi M, Schlessinger J & Giancotti FG 1995 Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. *EMBO Journal* **14** 470–481.
- McGlade J, Cheng A, Pelicci G, Pelicci PG & Pawson T 1992 Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases. *PNAS* **89** 8869–8873.
- Meng TC, Lee MS & Lin MF 2000 Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. *Oncogene* **19** 2664–2677.
- Meyer G & Feldman EL 2002 Signaling mechanisms that regulate actin-based motility processes in the nervous system. *Journal of Neurochemistry* **83** 490–503.
- Michels G, Er F, Eicks M, Herzig S & Hoppe UC 2006 Long-term and immediate effect of testosterone on single T-type calcium channel in neonatal rat cardiomyocytes. *Endocrinology* **147** 5160–5169.
- Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, Pawson T, Di Fiore PP, Lanfrancione L & Pelicci PG 1997 Opposite effects of the p52Shc/p46Shc and p66Shc splicing isoforms on the EGF receptor-MAP kinase-*fos* signaling pathway. *EMBO Journal* **16** 706–716.
- Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancione L & Pelicci PG 1999 The p66shc adaptor protein controls oxidative stress response and life span in mammals. *Nature* **402** 309–313.
- Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, Barone MV, Ametrano D, Zannini MS, Abbondanza C *et al.* 2000 Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. *EMBO Journal* **19** 5406–5417.
- Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, De Falco A, Nanayakkara M, Bottero D, De Stasio R, Varricchio L *et al.* 2006 Crosstalk between EGFR and extranuclear steroid receptors. *Annals of the New York Academy of Sciences* **1089** 194–200.

- Mignatti P, Morimoto T & Rifkin DB 1991 Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. *PNAS* **88** 11007–11011.
- Mundy GR 1997 Mechanisms of bone metastasis. *Cancer* **80** 1546–1556.
- Nakhla AM, Romas NA & Rosner W 1997 Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone-binding globulin. *Journal of Biological Chemistry* **272** 6838–6841.
- Nemoto S & Finkel T 2002 Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. *Science* **29** 2450–2452.
- Nemoto S, Combs CA, French S, Ahn BH, Fergusson MM, Balaban RS & Finkel T 2006 The mammalian longevity-associated gene product p66shc regulates mitochondrial metabolism. *Journal of Biological Chemistry* **281** 10555–10560.
- Northey JJ, Chmielecki J, Ngan E, Russo C, Annis MG, Muller WJ & Siegel PM 2008 Signaling through ShcA is required for transforming growth factor beta- and Neu/ErbB-2-induced breast cancer cell motility and invasion. *Molecular and Cellular Biology* **28** 3162–3176.
- Okada S, Kao AW, Ceresa BP, Blaikie P, Margolis B & Pessin JE 1997 The 66-kDa Shc isoform is a negative regulator of the epidermal growth factor-stimulated mitogen-activated protein kinase pathway. *Journal of Biological Chemistry* **272** 28042–28049.
- Okamoto T, Schlegel A, Scherer PE & Lisanti MP 1998 Caveolins, a family of scaffolding proteins for organizing 'preassembled signaling complexes' at the plasma membrane. *Journal of Biological Chemistry* **273** 5419–5422.
- Olson MF, Ashworth A & Hall A 1995 An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1. *Science* **269** 1270–1272.
- Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D, Martin-Padura I, Pelliccia G, Trinei M, Bono M et al. 2004 The life span determinant p66shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential. *Journal of Biological Chemistry* **279** 25689–25695.
- Pacini S, Pellegrini M, Migliaccio E, Patrussi L, Ulivieri C, Ventura A, Carraro F, Naldini A, Lanfrancone L, Pellicci P et al. 2004 p66SHC promotes apoptosis and antagonizes mitogenic signaling in T cells. *Molecular and Cellular Biology* **24** 1747–1757.
- Pages G, Lenormand P, L'Allemain G, Chambard JC, Meloche S & Pouyssegur J 1993 Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. *PNAS* **90** 8319–8323.
- Pandolfi S, Bonafe M, Di Tella L, Tiberi L, Salvioli S, Monti D & Sorbi S 2005 Franceschi Cp66Shc is highly expressed in fibroblasts from centenarians. *Mechanisms of Ageing and Development* **126** 839–844.
- Park YJ, Kim TY, Lee SH, Kim H, Kim SW, Shong M, Yoon YK, Cho BY & Park DJ 2005 p66shc expression in proliferating thyroid cells is regulated by thyrotropin receptor signaling. *Endocrinology* **146** 2473–2480.
- Pawson T & Scott JD 1997 Signaling through scaffold, anchoring, and adaptor proteins. *Science* **278** 2075–2080.
- Pellicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Pawson T & Pellicci PG 1992 A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. *Cell* **70** 93–104.
- Pellicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, Panayotou G, Waterfield MD, Ponzetto C, Pellicci PG et al. 1995 The mitogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. *Oncogene* **10** 1631–1638.
- Pierce KL, Premont RT & Lefkowitz RJ 2002 Seven-transmembrane receptors. *Nature Reviews. Molecular Cell Biology* **3** 639–650.
- Pontes JE, Rose NR, Ercole C & Pierce JM Jr 1981 Immunofluorescence for prostatic acid phosphatase: clinical applications. *Journal of Urology* **126** 187–189.
- La Porta CA 2000 Links nPKCdelta a new therapeutic marker for melanoma metastasis? *International Journal of Molecular Medicine* **5** 467–471.
- Price DT, Della Rocca G, Guo C, Ballo MS, Schwinn DA & Luttrell LM 1999 Activation of extracellular signal regulated kinase in human prostate cancer. *Journal of Urology* **162** 1537–1542.
- Radinsky R & Fidler IJ 1992 Regulation of tumor cell growth at organ-specific metastases. *In Vivo* **6** 325–331.
- Ratner S, Patrick P & Bora G 1992 Lymphocyte development of adherence and motility in extracellular matrix during IL-2 stimulation. *Journal of Immunology* **149** 681–688.
- Ravichandran KS 2001 Signaling via Shc family adapter proteins. *Oncogene* **20** 6322–6330.
- Ray P, Ghosh SK, Zhang DH & Ray A 1997 Repression of interleukin-6 gene expression by 17 beta-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. *FEBS Letters* **409** 79–85.
- Reif AE, Schlesinger RM, Fish CA & Robinson CM 1973 Acid phosphatase isozymes in cancer of the prostate. *Cancer* **31** 689–699.
- Ripple MO, Henry WF, Rago RP & Wilding G 1997 Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. *Journal of the National Cancer Institute* **89** 40–48.
- Ripple MO, Henry WF, Schwarze SR, Wilding G & Weindrich R 1999 Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. *Journal of the National Cancer Institute* **91** 1227–1232.
- Rosner W, Hryb DJ, Khan MS, Nakhla AM & Romas NA 1999 Androgen and estrogen signaling at the cell membrane via G-proteins and cyclic adenosine monophosphate. *Steroids* **64** 100–106.

- Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, Li W, Batzer A, Thomas S, Brugge J, Pelicci PG *et al.* 1992 Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. *Nature* **360** 689–692.
- Ruoslahti E & Reed JC 1994 Anchorage dependence, integrins, and apoptosis. *Cell* **77** 477–478.
- Sachs M, Weidner KM, Brinkmann V, Walther I, Obermeier A, Ullrich A & Birchmeier W 1996 Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. *Journal of Cell Biology* **133** 1095–1107.
- Safe S 2001 Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. *Hormones* **62** 231–252.
- Sakai H, Igawa T, Saha PK, Nomata K, Yushita Y, Kanetake H & Saito Y 1992 A case of prostatic carcinoma presenting as a metastatic orbital tumor. *Hinyokika Kyo. Acta Urologica Japonica* **38** 77–80.
- Sakai H, Yogi Y, Minami Y, Yushita Y, Kanetake H & Saito Y 1993 Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma. *Journal of Urology* **149** 1020–1023.
- Sato K, Gotoh N, Otsuki T, Kakumoto M, Aoto M, Tokmakov AA, Shibuya M & Fukami Y 1997 Tyrosine residues 239 and 240 of Shc are phosphatidylinositol 4,5-bisphosphate-dependent phosphorylation sites by c-Src. *Biochemical and Biophysical Research Communications* **240** 399–404.
- Schlaepfer DD, Jones KC & Hunter T 1998 Multiple Grb2-mediated integrin-stimulated signaling pathways to ERK2/mitogen-activated protein kinase: summation of both c-Src- and focal adhesion kinase-initiated tyrosine phosphorylation events. *Molecular and Cellular Biology* **18** 2571–2585.
- Solin T, Kontturi M, Pohlmann R & Vihko P 1990 Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. *Biochimica et Biophysica Acta* **1048** 72–77.
- Song RX, Zhang Z & Santen RJ 2005 Estrogen rapid action via protein complex formation involving ERalpha and Src. *Trends in Endocrinology and Metabolism* **16** 347–353.
- Stevenson LE & Frackelton AR Jr 1998 Constitutively tyrosine phosphorylated p52 Shc in breast cancer cells: correlation with ErbB2 and p66 Shc expression. *Breast Cancer Research and Treatment* **49** 119–128.
- Stevenson LE, Ravichandran KS & Frackelton AR Jr 1999 Shc dominant negative disrupts cell cycle progression in both G0-G1 and G2-M of ErbB2-positive breast cancer cells. *Cell Growth and Differentiation* **10** 61–71.
- Stewart LV, Lyles B, Lin MF & Weigel NL 2005 Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. *Journal of Steroid Biochemistry and Molecular Biology* **97** 37–46.
- Stracke ML, Engel JD, Wilson LW, Rechler MM, Liotta LA & Schiffmann E 1989 The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells. *Journal of Biological Chemistry* **264** 21544–21549.
- Sundareshan M, Yu ZX, Ferrans VJ, Sulciner DJ, Gutkind JS, Irani K, Goldschmidt-Clermont PJ & Finkel T 1996 Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. *Biochemical Journal* **318** 379–382.
- Taylor WR, Greenberg AH, Turley EA & Wright JA 1993 Cell motility, invasion, and malignancy induced by overexpression of K-FGF or bFGF. *Experimental Cell Research* **204** 295–301.
- Thomas D & Bradshaw RA 1997 Differential utilization of ShcA tyrosine residues and functional domains in the transduction of epidermal growth factor-induced mitogen-activated protein kinase activation in 293T cells and nerve growth factor-induced neurite outgrowth in PC12 cells. Identification of a new Grb2.Sos1 binding site. *Journal of Biological Chemistry* **272** 22293–22299.
- Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E, Milia E, Martin-Padura I, Raker VA, Maccarana M *et al.* 2002 A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. *Oncogene* **30** 3872–3878.
- Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA & Marcelli M 2004 Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. *Cancer Research* **64** 7156–7168.
- Velverde MA, Rojas P, Amigo J, Cosmelli D, Orio P, Bahamonde MI, Mann GE, Vergara C & Latorre R 1999 Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit. *Science* **285** 1929–1931.
- Veeramani S & Lin MF 2007 Role of reactive oxygen species in carcinogenesis. In *Redox Biochemistry*, pp 212–218. Ed R Banarjee. New Jersey: John Wiley & Sons Inc.
- Veeramani S, Yuan TC, Chen SJ, Lin FF, Petersen JE, Shaheduzzaman S, Srivastava S, MacDonald RG & Lin MF 2005a Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. *Endocrine-Related Cancer* **12** 805–822.
- Veeramani S, Igawa T, Yuan TC, Lin FF, Lee MS, Lin JS, Johansson SL & Lin MF 2005b Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. *Oncogene* **24** 7203–7212.
- Veeramani S, Yuan TC, Lin FF & Lin MF 2008 Mitochondrial redox signaling by p66Shc is involved in regulating androgenic growth stimulation of human prostate cancer cells. *Oncogene* **27** 5057–5068.
- Ventura A, Luzi L, Pacini S, Baldari CT & Pelicci PG 2002 The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter. *Journal of Biological Chemistry* **277** 22370–22376.

- Ventura A, Maccarana M, Raker VA & Pelicci PG 2004 A cryptic targeting signal induces isoform-specific localization of p46Shc to mitochondria. *Journal of Biological Chemistry* **279** 2299–2306.
- Wary KK, Mainiero F, Isakoff SJ, Marcantonio EE & Giancotti FG 1996 The adaptor protein Shc couples a class of integrins to the control of cell cycle progression. *Cell* **87** 733–743.
- Wary KK, Mariotti A, Zurzolo C & Giancotti FG 1998 A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. *Cell* **94** 625–634.
- Webster MA, Hutchinson JN, Rauh MJ, Muthuswamy SK, Anton M, Tortorice CG, Cardiff RD, Graham FL, Hassell JA & Muller WJ 1998 Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. *Molecular and Cellular Biology* **18** 2344–2359.
- Weigel NL 1996 Steroid hormone receptors and their regulation by phosphorylation. *Biochemical Journal* **319** 657–667.
- Weigel NL & Moore NL 2007 Kinases and protein phosphorylation as regulators of steroid hormone action. *Nuclear Receptor Signaling* **5** e005.
- Wong CW, McNally C, Nickbarg E, Komm BS & Cheskis BJ 2002 Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. *PNAS* **99** 14783–14788.
- Xie Y & Hung MC 1996 p66Shc isoform down-regulated and not required for HER-2/neu signaling pathway in human breast cancer cell lines with HER-2/neu overexpression. *Biochemical and Biophysical Research Communications* **221** 140–145.
- Yoshida S, Masaki T, Feng H, Yuji J, Miyauchi Y, Funaki T, Yoshiji H, Matsumoto K, Uchida N, Watanabe S et al. 2004 Enhanced expression of adaptor molecule p46 Shc in nuclei of hepatocellular carcinoma cells: study of LEC rats. *International Journal of Oncology* **25** 1089–1096.
- Yuan TC, Lin FF, Veeramani S, Chen SJ & Earp HS 2007 3rd & Lin MF 2007 ErbB-2 via PYK2 upregulates the adhesive ability of androgen receptor-positive human prostate cancer cells. *Oncogene* **26** 7552–7559.
- Zaccagnini G, Martelli F, Fasanaro P, Magenta A, Gaetano C, Di Carlo A, Biglioli P, Giorgio M, Martin-Padura I, Pelicci PG et al. 2004 p66ShcA modulates tissue response to hindlimb ischemia. *Circulation* **15** 2917–2923.
- Zheng DQ, Woodard AS, Fornaro M, Tallini G & Languino LR 1999 Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. *Cancer Research* **59** 1655–1664.
- Zhou MM, Ravichandran KS, Olejniczak EF, Petros AM, Meadows RP, Sattler M, Harlan JE, Wade WS, Burakoff SJ & Fesik SW 1995 Structure and ligand recognition of the phosphotyrosine binding domain of Shc. *Nature* **378** 584–592.